This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

Nurses play an important role in the administration of biosimilars and the education of patients receiving them.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective ...

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...

The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity ...

Meta: Blinatumomab plus chemotherapy, vs chemotherapy alone, significantly improved DFS rates and was well tolerated in ...